Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,364.00
Bid: 12,398.00
Ask: 12,400.00
Change: 268.00 (2.22%)
Spread: 2.00 (0.016%)
Open: 12,150.00
High: 12,440.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-EU chief faces grilling over shaky COVID-19 vaccine strategy

Tue, 02nd Feb 2021 17:36

* EU under fire over slow vaccine rollout, border checks
issue

* Von der Leyen says Commission has been 'quick on its feet'

* Sees easing of supply problems as production ramps up
(Updates after meetings)

By Philip Blenkinsop

BRUSSELS, Feb 2 (Reuters) - EU lawmakers questioned chief
executive Ursula von der Leyen for hours on Tuesday over the
slow rollout and shortage of COVID-19 vaccines as she took
responsibility for an export control plan that angered Britain
and Ireland.

Three groups in the European Parliament on Tuesday evening
grilled Von der Leyen, a German who tweeted and appeared only on
German television in the first few days after the bloc imposed
curbs on vaccine exports on Friday.

Another parliament session was set for Wednesday morning,
and the groups want the EU president to appear before a full
session of parliament next week.

The COVID-19 vaccine crisis, which came to a head with the
EU export controls, followed news that AstraZeneca would
cut its supply of vaccines to the bloc until March by 60% due to
production problems.

Even with the addition of an extra 9 million doses that von
der Leyen announced on Sunday, the shortfall is at least 50%.

Questions still surround the Commission's decision -
swiftly reversed - to invoke Article 16 of the Brexit
agreement's Northern Ireland protocol. The move, part of the
EU's effort to boost vaccine supply for its member states, would
have set up border checks on the island of Ireland.

Von der Leyen accepted responsibility for Commission acts
and decisions, a person at one of Tuesday's meetings said.

The European Commission president repeated to lawmakers
arguments she made to newspapers as she sought to defuse
criticism over the slow start to COVID-19 vaccinations and
outrage over the border checks issue.

Asked by the Irish Times if she would apologise, von der
Leyen said she regretted that Article 16 was in a "provisional
version" of the decision, but said the EU executive had been
"quick on its feet" to find another solution.

Dacian Ciolos, president of the liberal Renew Europe group,
said mistakes could have grave consequences. "We have no margin
for error in this process. Not only does the credibility of the
EU and in particular the European Commission depend on it but
also the health and wellbeing of our citizens," he said in a
statement.

Sophie in 't Veld, a Dutch liberal lawmaker, said von der
Leyen was relying on too narrow a circle of advisers.

"She's made a couple of big fat mistakes. Article 16 was
one," she told Reuters, adding that her tendency to speak only
to German media was another problem.

EU countries have so far given first doses to about 3% of
their populations, compared with 9% for the United States and
14% for Britain, according to Our World in Data.

Von der Leyen said the EU had lagged rivals by three to four
weeks because of a more rigorous approvals process. Supply
problems should ease in the second quarter of 2021, but
increasing production remained a challenge.
(Reporting by Philip Blenkinsop; additional reporting by John
Chalmers
Editing by Gareth Jones, Angus MacSwan and Cynthia Osterman)

More News
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.